Tiziana Life Sciences Ltd
TLSA Healthcare Biotechnology
Insiders bought in the last twelve months.
Follow TLSA
Tiziana Life Sciences Ltd (TLSA) Piotroski F-score
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CUE Cue Biopharma, Inc. compare | 5 |
| MOLN Molecular Partners AG Sponsored ADR compare | 2 |
| KRRO Korro Bio, Inc. compare | — |
| MSLE Satellos Bioscience Inc. compare | — |
| ALXO ALX Oncology Holdings Inc. compare | — |
| AVXL Anavex Life Sciences Corp. compare | — |
| ANTX AN2 Therapeutics, Inc. compare | — |
| ABOS Acumen Pharmaceuticals, Inc. compare | — |
| TLSA Tiziana Life Sciences Ltd | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover